The healthy cells receive a low dose or no radiation. Special scans can check whether your NET has these receptors. If your NET has somatostatin receptors, doctors can use these receptors to target ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Crinetics Pharmaceuticals (NasdaqGS:CRNX) with ...

Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...

Fintel reports that on January 22, 2025, Jefferies upgraded their outlook for Crinetics Pharmaceuticals (NasdaqGS:CRNX) from Hold to Buy. Analyst Price Forecast Suggests 94.74% Upside As of December ...

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

Analysts at TD Cowen started coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) in a research note issued on Tuesday, MarketBeat.com reports. The firm set a “buy” rating ...

Radioactive scans include: octreotide scans (or Octreoscans) – these are also called somatostatin receptor scintigraphy scans tektroyd scans gallium dotatate PET (positron emission tomography) scans ...